Palvella Therapeutics shares jumped 45% pre-market after reporting positive Phase 3 results for its QTORIN gel. The drug met primary and secondary endpoints for microcystic lymphatic malformations. Based on this success, the company plans to submit a New Drug Application to the FDA in the second half of 2026, with potential approval expected in early 2027.